CClinicalTrials.gg
CompletedNCT06952972MorphECOSUpdated May 1, 2025

MorphECOS - Evaluation of the Influence of Fatigue and Sleep on the Performance of 2nd Cycle Medical Students (OSCE)

An observational study in Fatigue Intensity, Sleep and Sleep Deprivation, sponsored by Claude Bernard University. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by Claude Bernard University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
619
Ages
18 Years and older
Sex
All
01

Study summary

Objective and Structured Clinical Examinations (OSCEs) has been incorporated recently in the certification process as a final national undergraduate ranking examination. This exam is a challenge for medical students.

The aim of this study is to better characterise the population of students taking the OSCEs on the subject of sleep and fatigue and to assess whether these factors have an impact on their performance in the OSCEs.

02

Conditions studied

  • Fatigue Intensity
  • Sleep
  • Sleep Deprivation
  • Circadian Rhythm
03

In context

Sleep Deprivation

300 studies on the registry are indexed under Sleep Deprivation; 60 are open to participants now.

This study's enrollment of 619 is above the median of 60 across 48 observational studies indexed under Sleep Deprivation.

Browse Sleep Deprivation studies →

Lead sponsor

Claude Bernard University is the lead sponsor of 29 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

2nd cycle médical program

Inclusion criteria

  • Subjects of legal age, enrolled in the 2nd cycle médical program at the Lyon Est Faculty of Medicine (Claude Bernard Lyon 1 University), taking part in the annual session (February or March 2025) of the faculty's OSCEs and having agreed to participate by completing and signing the dedicated written consent form.

Exclusion criteria

Exclusion Criteria:

  • abstenteism or Premature end to the OSCE session.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
619 participants (actual)
Patient registry
No

Groups and cohorts

  • 5th year of medical curriculum

    5th year of medical curriculum

  • 6th year of medical curriculum

    6th year of medical curriculum

06

What researchers measure

Primary outcomes

  1. PERFORMANCE

    Score at the objectif structured clinical examination exam from 0 minimum to 200 points maximum

    Time frame: obtained seven days after the objectif structured clinical examination

Secondary outcomes

  1. Significant difference in student performance per station and per item

    Significant difference in student performance per station and per item

    Time frame: obtained seven days after the objectif structured clinical examination

  2. Significant difference in Visual Analog Scale response according to the different profiles

    Significant difference in Visual Analog Scale response according to the different profiles

    Time frame: Two times : 1 hour before and 1 hour after the OSCE session

07

Study locations

1 site
  • Claude Bernard University
    Lyon, 69003, France
08

References and documents

Individual participant data

Plan to share: No — Not provided for in the protocol.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06952972
Lead sponsor
Claude Bernard University
Responsible party
Evan GOUY (Principal Investigator, Claude Bernard University) — Principal investigator
First posted
May 1, 2025
Start date
Jan 27, 2025
Primary completion
Mar 20, 2025
Completion
Mar 20, 2025
Last update
May 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion